WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006084145) METHODS OF USING IL-1 ANTAGONISTS TO REDUCE C-REACTIVE PROTEIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/084145    International Application No.:    PCT/US2006/003866
Publication Date: 10.08.2006 International Filing Date: 02.02.2006
IPC:
A61K 38/16 (2006.01), A61K 39/395 (2006.01), A61K 38/20 (2006.01), A61P 19/02 (2006.01), A61P 29/00 (2006.01), A61P 9/10 (2006.01)
Applicants: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US) (For All Designated States Except US).
WEINSTEIN, Steven, P. [US/US]; (US) (For US Only).
KAROW, Margaret [US/US]; (US) (For US Only).
RADIN, Allen [US/US]; (US) (For US Only).
ROBERTS, William [US/US]; (US) (For US Only).
WANG, Li-Hsien [--/US]; (US) (For US Only).
MELLIS, Scott [US/US]; (US) (For US Only)
Inventors: WEINSTEIN, Steven, P.; (US).
KAROW, Margaret; (US).
RADIN, Allen; (US).
ROBERTS, William; (US).
WANG, Li-Hsien; (US).
MELLIS, Scott; (US)
Agent: GREGG, Valeta; Regeneron Pharmaceuticals, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US)
Priority Data:
60/649,200 02.02.2005 US
60/650,339 04.02.2005 US
Title (EN) METHODS OF USING IL-1 ANTAGONISTS TO REDUCE C-REACTIVE PROTEIN
(FR) PROCEDES D'UTILISATION D'ANTAGONISTES IL-1 AFIN DE REDUIRE LA PROTEINE C-REACTIVE
Abstract: front page image
(EN)Methods of reducing C-reactive protein (CRP) in a subject, comprising administering to the subject a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein CRP is reduced. The IL-1 antagonist is preferably an IL-1-binding fusion protein (IL-1 trap), preferably comprising.
(FR)Procédé de réduction d'une protéine C-réactive (CRP) chez un sujet, consistant à administrer au sujet une quantité thérapeutique d'un antagoniste de l'interleukine 1 (IL-1), CRP étant réduite. L'antagoniste IL-1 est, préférablement, une protéine de fusion de liaison IL-1 (piège IL-1), comprenant préférablement SEQ ID N°2.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)